Flagship Biosciences to Present Computational Tissue Analysis Solutions for Advancing Drug Development at AACR Annual Meeting

Visit AACR booth 3404 to learn more about Flagship solutions

WESTMINSTER, Colo. (PRWEB) April 12, 2018

Flagship Biosciences’ cTA and decision support platform will be featured in four scientific poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, in Chicago.

As the leading partner for drug developers investigating tissue-based biomarkers, Flagship applies computational tissue analysis to provide quantitative, contextual data that drives more confident clinical trial decisions. Flagship scientists will present the company’s latest developments in immune and tumor cell analysis.

Scientific poster presentation details:

•     Analysis of Multiplexed Immunotherapy Targets and Secreted Ligands Using Computational Tumor Microenvironment Profiling, Monday, Apr. 16, 8 am – 12 pm, Poster Section 32, #1720.
•     Computational Analysis of Multiplexed Immunohistochemistry for Understanding Immune Profiles in Clinical Biopsies, Monday, Apr. 16, 8 am – 12 pm, Poster Section 31, #1694.
•     Comparison of Multiplexed Imaging Mass Cytometry in FFPE Tissue to Monoplex Immunohistochemistry, Tuesday, Apr. 17, 8 am – 12 pm, Poster Section 1, #3037.
•     A Methodology for Designing and Validating Computational Pathology Scores for Immune Cell Clustering in Tumor Biopsies, Wednesday, Apr. 18, 8 am – 12 pm, Poster Section 31, #5684.

The American Association for Cancer Research holds the AACR Annual Meeting to bring together oncologists, laboratory scientists, medical professionals, nurses, scientists and patients together to enrich and enlighten them with the current practices and techniques in the field of cancer prevention and treatment.

Flagship’s booth, #3404, will be located on the right side of the AACR Exhibit Hall, in the first row of exhibits. Contact Flagship at info@flagshipbio.com to schedule a meeting at AACR.

About Flagship Biosciences
Flagship Biosciences helps drug developers confidently define their path to success. By leveraging our unique cTA and decision support platform, we provide quantitative and contextual tissue interpretation to make timely decisions. For more information on how Flagship accelerates drug development, please visit the Company’s website: http://www.flagshipbio.com.

Media Contact
Amy Shannon
VP, Sales & Marketing
ashannon@flagshipbio.com
303.608.9008

For the original version on PRWeb visit: http://www.prweb.com/releases/2018/04/prweb15393568.htm